Neumora Therapeutics (NMRA) Competitors $1.85 +0.14 (+8.19%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$1.88 +0.03 (+1.89%) As of 07/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. CMRX, CRON, QURE, OCS, ANAB, BGM, CRMD, VIR, KALV, and AMLXShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Chimerix (CMRX), Cronos Group (CRON), uniQure (QURE), Oculis (OCS), AnaptysBio (ANAB), BGM Group (BGM), CorMedix (CRMD), Vir Biotechnology (VIR), KalVista Pharmaceuticals (KALV), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Chimerix Cronos Group uniQure Oculis AnaptysBio BGM Group CorMedix Vir Biotechnology KalVista Pharmaceuticals Amylyx Pharmaceuticals Neumora Therapeutics (NASDAQ:NMRA) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Do analysts prefer NMRA or CMRX? Neumora Therapeutics currently has a consensus price target of $7.14, indicating a potential upside of 286.10%. Chimerix has a consensus price target of $8.53, indicating a potential downside of 0.08%. Given Neumora Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is NMRA or CMRX more profitable? Chimerix's return on equity of -50.78% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Neumora TherapeuticsN/A -84.79% -77.57% Chimerix N/A -50.78%-44.94% Which has more volatility & risk, NMRA or CMRX? Neumora Therapeutics has a beta of 2.75, meaning that its stock price is 175% more volatile than the S&P 500. Comparatively, Chimerix has a beta of -0.17, meaning that its stock price is 117% less volatile than the S&P 500. Does the media prefer NMRA or CMRX? In the previous week, Neumora Therapeutics had 2 more articles in the media than Chimerix. MarketBeat recorded 2 mentions for Neumora Therapeutics and 0 mentions for Chimerix. Neumora Therapeutics' average media sentiment score of 0.50 beat Chimerix's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Neumora Therapeutics Positive Chimerix Neutral Do institutionals & insiders believe in NMRA or CMRX? 47.7% of Neumora Therapeutics shares are owned by institutional investors. Comparatively, 45.4% of Chimerix shares are owned by institutional investors. 26.8% of Neumora Therapeutics shares are owned by company insiders. Comparatively, 13.1% of Chimerix shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has stronger valuation and earnings, NMRA or CMRX? Chimerix has higher revenue and earnings than Neumora Therapeutics. Chimerix is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeumora TherapeuticsN/AN/A-$243.79M-$1.61-1.15Chimerix$212K3,778.71-$82.10M-$0.99-8.63 SummaryNeumora Therapeutics beats Chimerix on 9 of the 14 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$276.59M$2.95B$5.55B$9.40BDividend YieldN/A2.47%3.75%4.03%P/E Ratio-1.1519.7528.0119.82Price / SalesN/A300.24432.8198.20Price / CashN/A42.5936.1658.27Price / Book1.047.678.125.65Net Income-$243.79M-$55.28M$3.25B$257.91M7 Day Performance43.41%4.85%1.68%3.38%1 Month Performance137.18%11.70%7.30%11.11%1 Year Performance-83.60%3.69%32.89%18.99% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics2.3944 of 5 stars$1.85+8.2%$7.14+286.1%-83.2%$276.59MN/A-1.15108Positive NewsAnalyst ForecastGap UpHigh Trading VolumeCMRXChimerix0.6089 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CRONCronos Group2.0409 of 5 stars$2.07-1.0%N/A-14.5%$798.36M$117.61M15.92450QUREuniQure1.7625 of 5 stars$14.55+1.0%$37.82+159.9%+92.2%$797.05M$27.12M-3.31500Positive NewsOCSOculis1.9681 of 5 stars$18.16+0.6%$35.33+94.6%+49.8%$792.90MN/A-6.882ANABAnaptysBio1.6462 of 5 stars$26.95+2.9%$42.38+57.2%-24.8%$791.79M$91.28M-5.56100BGMBGM GroupN/A$8.08-13.2%N/AN/A$785.54M$25.10M0.00298CRMDCorMedix2.5625 of 5 stars$11.36+1.2%$17.14+50.9%+133.0%$770.49M$82.55M51.6430VIRVir Biotechnology3.5796 of 5 stars$5.50-2.7%$30.25+450.0%-47.1%$760.32M$74.21M-1.30580News CoverageKALVKalVista Pharmaceuticals4.0725 of 5 stars$15.22+4.8%$26.29+72.7%+8.4%$760.24MN/A-4.12100Analyst RevisionAMLXAmylyx Pharmaceuticals3.4144 of 5 stars$8.41+9.5%$11.75+39.7%+317.0%$749.68M-$1.27M-2.70200Analyst UpgradeHigh Trading Volume Related Companies and Tools Related Companies Chimerix Competitors Cronos Group Competitors uniQure Competitors Oculis Competitors AnaptysBio Competitors BGM Group Competitors CorMedix Competitors Vir Biotechnology Competitors KalVista Pharmaceuticals Competitors Amylyx Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 7/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
